254 related articles for article (PubMed ID: 33086177)
21. Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR)
Kang Y; Xie L; Yang J; Cui J
Front Cell Infect Microbiol; 2023; 13():1023948. PubMed ID: 37457958
[TBL] [Abstract][Full Text] [Related]
22. Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies.
Xu C; Wei X; Jin Y; Bai F; Cheng Z; Chen S; Pan X; Wu W
Microbiol Spectr; 2022 Oct; 10(5):e0139022. PubMed ID: 35972286
[TBL] [Abstract][Full Text] [Related]
23.
Huang YS; Chen PY; Chou PC; Wang JT
Microbiol Spectr; 2023 Jun; 11(3):e0056923. PubMed ID: 37154758
[TBL] [Abstract][Full Text] [Related]
24. Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures.
Ruiz VH; Gill CM; Nicolau DP
J Antimicrob Chemother; 2024 Mar; 79(3):546-551. PubMed ID: 38217443
[TBL] [Abstract][Full Text] [Related]
25. The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.
Nichols WW; Bradford PA; Stone GG
J Antimicrob Chemother; 2023 Apr; 78(4):871-892. PubMed ID: 36883356
[TBL] [Abstract][Full Text] [Related]
26. Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India.
Sree RA; Gupta A; Gupta N; Veturi S; Reddy LSK; Begum M; Shravani E; Challa HR; Reddy SS; Singamsetty A; Arumilli M; Reddy PN; Tirlangi PK
Infection; 2024 Apr; 52(2):429-437. PubMed ID: 37697224
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales.
Kelley CJ; Kennedy-Mendez A; Walser ON; Thwaites MT; Arhin FF; Pillar CM; Hufnagel DA
Microbiol Spectr; 2022 Dec; 10(6):e0360122. PubMed ID: 36342288
[TBL] [Abstract][Full Text] [Related]
28. Aztreonam-avibactam synergy, a validation and comparison of diagnostic tools.
Verschelden G; Noeparast M; Stoefs A; Van Honacker E; Vandoorslaer K; Vandervore L; Olbrecht M; Van Damme K; Demuyser T; Piérard D; Wybo I
Front Microbiol; 2023; 14():1322180. PubMed ID: 38094627
[TBL] [Abstract][Full Text] [Related]
29. In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Bernabeu S; Dortet L
Antibiotics (Basel); 2023 Sep; 12(10):. PubMed ID: 37887194
[TBL] [Abstract][Full Text] [Related]
30. Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections-In Vitro Susceptibility Testing.
Brauncajs M; Bielec F; Malinowska M; Pastuszak-Lewandoska D
Pharmaceuticals (Basel); 2024 Mar; 17(3):. PubMed ID: 38543169
[TBL] [Abstract][Full Text] [Related]
31. Multicenter Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam Broth Disk Elution Test.
Harris H; Tao L; Jacobs EB; Bergman Y; Adebayo A; Tekle T; Lewis S; Dahlquist A; Abbey TC; Wenzler E; Humphries R; Simner PJ
J Clin Microbiol; 2023 May; 61(5):e0164722. PubMed ID: 37070979
[TBL] [Abstract][Full Text] [Related]
32. Clinical Features and Outcomes of Infections Caused by Metallo-β-Lactamase-Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area.
Falcone M; Giordano C; Leonildi A; Galfo V; Lepore A; Suardi LR; Riccardi N; Barnini S; Tiseo G
Clin Infect Dis; 2024 May; 78(5):1111-1119. PubMed ID: 38036465
[TBL] [Abstract][Full Text] [Related]
33. Determination of aztreonam/ceftazidime-avibactam synergism and proposal of a new methodology for the evaluation of susceptibility in vitro.
Collar GDS; Moreira NK; Becker J; Barth AL; Caierão J
Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116236. PubMed ID: 38537506
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of Antibiotic Activity of Aztreonam against Metallo-β-Lactamase-Producing Multidrug-Resistant
Lee S; Lee T; Kim MK; Ahn JH; Jeong S; Park KH; Chong Y
Pharmaceutics; 2024 Jan; 16(2):. PubMed ID: 38399246
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against
Hu Y; Chen J; Huang L; Liu C; Zhou H; Zhang R
J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36753319
[No Abstract] [Full Text] [Related]
36. Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter.
Wu S; Ma K; Feng Y; Zong Z
Ann Clin Microbiol Antimicrob; 2023 Jun; 22(1):49. PubMed ID: 37365592
[TBL] [Abstract][Full Text] [Related]
37. Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed
Gupta N; Boodman C; Prayag P; Manesh A; Kumar TP
Expert Rev Anti Infect Ther; 2024 Apr; 22(4):203-209. PubMed ID: 38258529
[TBL] [Abstract][Full Text] [Related]
38. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
Le Terrier C; Nordmann P; Freret C; Seigneur M; Poirel L
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0033923. PubMed ID: 37255469
[TBL] [Abstract][Full Text] [Related]
39. Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria.
Simon M; Gerlach RG; Pfeifer Y; Pfennigwerth N; Gatermann SG; Schröder A; Hiergeist A; Hamprecht A; Rügamer T; Gessner A; Jantsch J
Front Microbiol; 2022; 13():977330. PubMed ID: 36483203
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of aztreonam-avibactam and comparators against Metallo-β-Lactamase-producing Enterobacterales from ATLAS Global Surveillance Program, 2016-2020.
Rossolini GM; Arhin FF; Kantecki M
J Glob Antimicrob Resist; 2024 Mar; 36():123-131. PubMed ID: 38154750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
